AbbVie, Scripps Research to Collaborate on New Covid Treatments
March 15 2022 - 8:50AM
Dow Jones News
By Will Feuer
AbbVie Inc. said it is collaborating with non-profit biomedical
research and drug discovery institute Scripps Research to develop
potential new antiviral treatments for Covid-19.
"We are committed to bringing differentiated, next generation
oral antiviral treatments to patients and ensuring broad access to
address the diverse treatment needs around the world," AbbVie Chief
Scientific Officer Tom Hudson said.
The initial Covid-19 research program at Calibr, Scripps' drug
discovery and development division, was supported by funding from
the Bill & Melinda Gates Foundation.
"We believe our SARS-CoV-2 research program has the potential to
impact significantly the ongoing gaps in patient needs to move from
pandemic to endemic COVID-19," Scripps Research Chief Executive
Peter Schultz said.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
March 15, 2022 08:35 ET (12:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024